We are passionate about cell biology
and leverage our unique cell metabolism and AI-powered data analysis platforms
to shorten the time to critical insights and improve human health
Our products
We are experts in single-cell analysis, metabolism, and AI
Proper metabolism is key for cell fate and function in the body.
Our unique IVD and cell therapy reagents allow monitoring pf cellular fitness and metabolism.
We leverage our proprietary platform to decipher single cell metabolic programs. In addition, we help clinicians infer clinical outcomes of disease from our In vitro diagnostics, and improve optimization of cell therapy products.
METAflow is the only software
able to offer an “augmented intelligence” solution allowing users to get quick, objective and reproducible results.
A highly differentiated approach to modern flow- and mass-cytometry analysis, for use in research and clinical diagnostics.
Meet our team
A multidisciplinary team of Entrepreneurs, Biologists, Data Scientists, and expert Mathematicians
from 12 nationalities, based in Paris, France, and the USA
Our latest news
February 28, 2025Quality management system certification ISO 13485:2016 renewed
February 23, 2024Translating the regulatory landscape of medical devices to create fit-for-purpose artificial intelligence (AI) cytometry solutions
June 20, 2023Raising awareness on rare diseases like Glut1DS at the annual meeting of EPNS 2023
May 3, 2023Coverage recommandation for our innovative IVD test METAglut™ by French National Authority for Health (HAS)
April 27, 2023Evaluation of our innovative IVD test METAglut™ published by French National Authority for Health (HAS)
April 19, 2023Prospective Multicenter Validation of a Simple Blood Test for the Diagnosis of Glut1 Deficiency Syndrome
November 19, 2022EIC Accelerator Funding awarded to drive innovation and next-level growth
September 21, 2022Introducing METAflow our innovative AI cytometry data analysis platform at ESCCA 2022
April 7, 2022Testimonial from Dr. Domitille Gras on our innovative IVD test METAglut™ during World Health Day 2022
February 17, 2022Revealing key findings from our METAglut1™ validation study at the meeting of SENP 2022
February 2, 2022Poster presentation on METAglut1™ our innovative IVD blood test at the meeting of SFNP 2022
September 16, 2021Strategic partnership with Sebia to develop innovative in vitro diagnostics
June 19, 2021Latest Findings on our Validation Study Announced at the European GLUT1D Conference
June 11, 2021Updates at the European Conference on Glut1 Deficiency 2021
March 22, 2021Quality management system certification ISO 13485:2016 obtained
January 15, 2020New results on METAglut1™ validation study presented at the meeting of SFNP 2020
December 16, 2019Early patient access to health technologies: Is innovation needed for early management?
July 11, 2019Attending the 2019 Summit of the Glut1 Deficiency Foundation to talk about METAglut1™ our innovative IVD blood test
June 21, 2019Proud Laureate of the PhD Paris Region Funding Initiative
June 10, 2019Usefulness of diagnostic tools in a GLUT1 deficiency syndrome patient with 2 inherited mutations
March 22, 2019Oral presentation on METAglut1™ our innovative IVD blood test at the meeting of SENP 2019
February 20, 2019€1M Grant from Bpifrance’s Innovation Prize
January 16, 2019Poster presentation on METAglut1™ our innovative IVD blood test at the meeting of SFNP 2019
June 22, 2018Booth at the European Conference on Glut1 Deficiency 2018
June 11, 2018€3.2M Grant awarded: major boost for the launch of our validation study
April 27, 2018Booth to discuss latest results on METAglut1™ at the meeting of SENP 2018
July 13, 2017Attending the summit of the Glut1 Deficiency Foundation 2017 to talk about METAglut1™ our innovative IVD blood test
July 1, 2017A simple blood test expedites the diagnosis of glucose transporter type 1 deficiency syndrome
June 12, 2017Results of our first study with AP-HP and the ICM on our innovative IVD test METAglut™ published in Annals of Neurology
February 15, 2017European regulatory approval successfully obtained for METAglut1™ our innovative IVD test for Glut1DS
February 2, 2017Launch of our first innovative IVD test METAglut1™ to aid the diagnosis of Glut1DS developed with our partner CERBA HealthCare
November 18, 2016Company milestones shared at the Actionaria Event 2016
November 7, 2016Alliance with Cerba HealthCare to advance metabolomics and drive diagnostic innovations
October 10, 2016Inauguration meeting with our international scientific board of leading experts to enhance GLUT1DS diagnosis
October 7, 2016Attending the first European Conference on Glut1 Deficiency
April 16, 2016Exclusive Interview with BFM Business Radio: our participation in the BigBooster Program
April 12, 2016Cell surface Glut1 levels distinguish human CD4 and CD8 T lymphocyte subsets with distinct effector functions
March 15, 2016Metabolic Reprogramming Supports IFN-γ Production by CD56bright NK Cells
February 29, 2016Disruption of Glut1 in Hematopoietic Stem Cells Prevents Myelopoiesis and Enhanced Glucose Flux in Atheromatous Plaques of ApoE(-/-) Mice
February 10, 2016Selected for the BigBooster Acceleration Program
August 6, 2015Cytostatic Effect of Repeated Exposure to Simvastatin: A Mechanism for Chronic Myotoxicity Revealed by the Use of Mesodermal Progenitors Derived from Human Pluripotent Stem Cells
July 1, 2015Company Strategy Vision Presented at the First International Biotechnology Meeting
Our achievements
February 2024
METAglut1™ obtains universal national coverage
in France as recommended by the
French National Authority for Health
(Haute Autorité de Santé, HAS)July 2023
Showcase of early version of
METAflow for research
October 2022
Laureate of EIC (European Innovation Council) accelerator program to develop METAflow™
for clinical applications
June 2021
Partnership with Sebia to develop innovative IVDs (In Vitro Diagnositics)
for Hemato-OncologyJanuary 2019
Winner of the Innovation Prize from Bpifrance
to develop the METAbolism platform
for diagnostics in OncologyJune 2018
Laureate of H2020 Innovation Grant
to fund METAglut1™ 's validation studyMarch 2018
METAglut1™ obtains the Forfait Innovation
(fast track reimbursement program)
after its CE-Marking in 2017
Our worldwide partnerships
At METAFORA, we are building an ecosystem to ensure that our solutions meet expectations.
Patient associations help us to deeply understand unmet needs, when leading medical researchers collaborate with us to develop and validate our solutions. We are grateful to many institutions for their continuous support and we are also working hard to extend our collaborations to make our solutions available for daily clinical practice.
Patient associations
Research collaborations
Supporting organizations
Partnerships
Contact us
METAFORA Biosystems
Pépinière Paris Biotech Santé
29 rue du Faubourg Saint Jacques
75014 Paris, FRANCE
METAFORA biosystems, Inc.
Suite 417
100 South State Street
IL 60603, Chicago, USA
For any request, or if you would like to join the team, do not hesitate to contact us via
